Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Japan AS Represented By Director General Of National Institute Of Infectious Diseases operates within the Biotechnology & Pharmaceuticals technology area. The portfolio currently includes 2 pending office actions. These actions are distributed across 2 distinct art units, indicating that the active filings are being reviewed in different specialized sections of the patent office.
The prosecution involves 2 distinct examiners, ensuring that each pending office action is handled by a different individual. BLUMEL, BENJAMIN P is identified as the busiest examiner, currently responsible for 1 pending office action. This means that the 2 pending office actions are split among the 2 distinct examiners involved in the portfolio's oversight.
For the practitioner, the presence of 2 distinct art units and 2 distinct examiners suggests a lack of concentration. Each filing requires a unique approach tailored to the specific examiner and art unit. The outcome of the 1 pending office action under BLUMEL, BENJAMIN P will account for a portion of the current active prosecution workload. Success in these separate tracks requires managing the distinct expectations of 2 different examiners simultaneously.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BLUMEL, BENJAMIN P | 1 | 70.8% | +30.5% |
| ROSSI, JULIA ANNE LORRAIN | 1 | 45.7% | +61.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906956 | METHOD FOR CREATING MULTIMERIC IgA ANTIBODY, AND MULTISPECIFIC MULTIMERIC IgA ANTIBODY | ROSSI, JULIA ANNE LORRAIN | 60d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906956 | METHOD FOR CREATING MULTIMERIC IgA ANTIBODY, AND MULTISPECIFIC MULTIMERIC IgA ANTIBODY | ROSSI, JULIA ANNE LORRAIN | 60d overdue |
| 18341960 | METHOD FOR PRODUCING INFLUENZA HA SPLIT VACCINE | BLUMEL, BENJAMIN P | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18341960 | METHOD FOR PRODUCING INFLUENZA HA SPLIT VACCINE | BLUMEL, BENJAMIN P | 1671 | §112DP | Non-Final OA | — | Pending | Jun 27, 2023 |
| 17906956 | METHOD FOR CREATING MULTIMERIC IgA ANTIBODY, AND MULTISPECIFIC MULTIMERIC IgA ANTIBODY | ROSSI, JULIA ANNE LORRAIN | 1615 | §102§103 | Final Rejection | 60d overdue | Pending | Sep 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial